6681.HK

BrainAurora Medical Tech Ltd. (6681.HK) announced on Friday that its CEO and chief research officer Wang Xiaoyi resigned, effective Thursday, due to health issues caused by worsening depression.

The company said that Wang’s condition deteriorated during its IPO process, and he has decided to suspend all work to focus on treatment and recovery. It added the decision also helps ensure stable corporate governance. CTO and COO Cai Longjun will assume Wang’s duties.

Based in the city of Shaoxing in East China’s Zhejiang province, BrainAurora says it is China’s first company to integrate neuroscience and AI to develop medical-grade digital therapeutics. Its product pipeline spans vascular diseases, neurodegenerative conditions, mental health disorders and developmental disorders in children. Last year the company’s revenue rose 82% to 122 million yuan ($17 million), while its net loss narrowed 44.7% to 198 million yuan.

The company’s stock opened higher on Friday after the announcement and closed at HK$ 6.99 by the midday break, up 1.8%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Expansion into Middle East sends shares soaring, but Zhida's valuation looks steep

Middle East expansion charges up Zhida’s stock

Shares of the EV charger maker, whose backers include BYD, jumped nearly 10% after announcing its latest expansion plan Key Takeaways: Zhida plans to enter the Middle East, targeting Saudi…
51World faces IPO reality check

Earth Clone designer 51World faces IPO reality check

The maker of “digital twin” tools and simulations, including a plan for a virtual copy of the earth’s surface, is grappling with earnings pressure and rising competition Key Takeaways: The…